LADA and MODY: Rare Types of Diabetes

LADA and MODY: Rare Types of Diabetes

While Type 1 and Type 2 diabetes account for over 95% of all diabetes cases, there are lesser-known forms that are frequently misdiagnosed. LADA (Latent Autoimmune Diabetes in Adults) and MODY (Maturity-Onset Diabetes of the Young) are two important rare types that every person with diabetes — and their doctors — should be aware of.

LADA: Latent Autoimmune Diabetes in Adults

LADA is a form of autoimmune diabetes that develops in adults, typically over 30. It is often misdiagnosed as Type 2 diabetes because it initially presents with features of Type 2 (adult onset, may not require insulin immediately). However, LADA is actually a slow-progressing form of Type 1 diabetes.

Key characteristics:

• Adult onset (usually 30-50 years)
• Presence of autoantibodies (GAD65, IA-2, ZnT8) — same as Type 1
• Gradual beta-cell destruction (slower than Type 1)
• May not require insulin for 6 months to several years after diagnosis
• Often lean or normal weight (unlike Type 2)
• Accounts for 2-12% of all diabetes cases (estimated 5-10% in Europe)

A 2020 study in The Lancet Diabetes & Endocrinology found that 10% of adults diagnosed with Type 2 diabetes actually have LADA, and misdiagnosis leads to inappropriate treatment with oral medications instead of insulin.

How LADA differs from Type 2:

• Autoantibodies present (absent in Type 2)
• C-peptide levels decline over time (stable in Type 2)
• Less insulin resistance
• Lower BMI at diagnosis
• Progresses to insulin dependence faster

Treatment: LADA patients eventually require insulin. Starting insulin early may preserve beta-cell function. Oral medications (especially sulfonylureas) may accelerate beta-cell destruction and should be avoided.

MODY: Maturity-Onset Diabetes of the Young

MODY is a group of monogenic diabetes disorders caused by mutations in a single gene. It is inherited in an autosomal dominant pattern, meaning 50% of children of an affected parent will develop it.

Key characteristics:

• Diagnosed before age 25 (often in adolescence or young adulthood)
• Strong family history (3+ generations affected)
• No autoantibodies (unlike Type 1)
• No insulin resistance (unlike Type 2)
• Accounts for 1-5% of all diabetes cases
• Often misdiagnosed as Type 1 or Type 2

A 2019 study in Diabetes Care found that 80% of MODY cases are misdiagnosed, leading to inappropriate treatment.

Common MODY subtypes:

• MODY 1 (HNF4A): Reduced insulin secretion. Responds to sulfonylureas.
• MODY 2 (GCK): Mild, stable hyperglycemia. Often doesn't require treatment. Most common subtype (30-50% of MODY cases).
• MODY 3 (HNF1A): Progressive beta-cell dysfunction. Responds excellently to sulfonylureas. Most common in Europe.
• MODY 5 (HNF1B): Associated with kidney abnormalities and genital malformations.

Treatment: MODY treatment depends on the subtype. MODY 2 usually needs no treatment. MODY 1 and 3 respond well to low-dose sulfonylureas. MODY 5 may require insulin.

When to Suspect LADA or MODY

Suspect LADA if:

• Adult diagnosed with Type 2 diabetes who is lean
• Rapid progression to insulin requirement
• Family history of autoimmune disease
• Poor response to oral medications

Suspect MODY if:

• Diabetes diagnosed before age 25
• Strong family history (3+ generations)
• Negative autoantibodies
• Normal BMI
• Mild, stable hyperglycemia (MODY 2)

Genetic Testing

Genetic testing is the gold standard for MODY diagnosis. It is recommended for:

• Diabetes diagnosed before age 25 with negative autoantibodies
• Strong family history of diabetes
• Mild, stable fasting hyperglycemia (suggestive of MODY 2)

For LADA, testing for GAD65 antibodies is the key diagnostic step.

Conclusion

LADA and MODY are rare but important forms of diabetes that are frequently misdiagnosed. LADA is a slow-progressing autoimmune diabetes in adults; MODY is a genetic form affecting young people. Proper diagnosis through antibody testing and genetic testing ensures appropriate treatment and better outcomes.

References:

• Tuomi, T., et al. (1993). Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes, 42(1), 114-119.
• Hattersley, A.T., & Patel, K.A. (2017). Precision diabetes: learning from monogenic diabetes. Diabetologia, 60(5), 769-777.
• Shields, B.M., et al. (2017). The development and validation of a clinical prediction model to determine the probability of MODY. Diabetologia, 60(10), 1924-1931.
• Fourlanos, S., et al. (2005). A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care, 28(5), 1090-1095.
• Fajans, S.S., & Bell, G.I. (2011). MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care, 34(8), 1878-1884.